Juan Pablo Frias

Insider

First SEC filing: June 12, 2024 · Latest: June 12, 2024

On this page

Insider at

0 buys (P) 0 sells (S) Net: $0 + 3 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
May 31, 2024	BMEA	A	349	$8.94	$3,120	349 Direct	—	Acquired	-84.7% (price as of 2026-08-21)
Jan. 17, 2024	BMEA	A	111,090	—	—	111,090 Direct	—	Acquired	(price as of 2026-08-21)
Aug. 31, 2023	BMEA	A	300,000	—	—	300,000 Direct	—	Acquired	(price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Jan. 17, 2024	BMEA	Stock Option (Right to Buy)	Common Stock (111,090)	$14.44	Jan. 16, 2034	111,090	Acquired
Aug. 31, 2023	BMEA	Stock Option (Right to Buy)	Common Stock (300,000)	$16.87	Aug. 30, 2033	300,000	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Matched by name from proxy statements (DEF 14A) — verify against the filing.

M.D. (5)(7) Former Chief Medical Officer

Fiscal year	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension change	Other	Total
2025	$325,000	—	—	—	—	—	$65,326	$549,037
2023	$168,403	$75,485	—	—	—	—	$12,598	$3,932,476

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.